Alnylam presents new data from the helios-b phase 3 study of vutrisiran in patients with attr amyloidosis with cardiomyopathy (attr-cm) at the american college of cardiology's annual scientific session 2025

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced moderated poster presentations of new data from the landmark helios-b phase 3 clinical trial, which evaluated vutrisiran for the treatment of attr amyloidosis with cardiomyopathy (attr-cm) in a population representative of today's patients. data were presented at the american college of cardiology's annual scientific session (acc.25) held in chicago, illinois.
ALNY Ratings Summary
ALNY Quant Ranking